| Lipids Management |
1 |
1 |
| Atherosclerosis |
0 |
0.99 |
| Acute Coronary Syndrome |
0 |
0.58 |
| Statins |
0 |
0.56 |
| Cardiovascular Risk Management |
0 |
0.46 |
| Renal Failure |
0 |
0.29 |
| Chronic Kidney Disease |
0 |
0.25 |
| Heart |
0 |
0.25 |
| Liver Disease |
0 |
0.22 |
| Renal Disease |
0 |
0.22 |
| Patient Safety |
0 |
0.21 |
| Clinical Guidelines |
0 |
0.19 |
| Infarction |
0 |
0.19 |
| Ischemia |
0 |
0.19 |
| Kidney |
0 |
0.19 |
| LDL Cholesterol |
0 |
0.19 |
| Liver |
0 |
0.19 |
| Familial Mediterranean Fever |
0 |
0.18 |
| Cerebrovascular Accident |
0 |
0.17 |
| Myocardial Infarction (MI) |
0 |
0.17 |
| PCSK9 |
0 |
0.17 |
| Biologic Therapy |
0 |
0.15 |
| Adverse Effects |
0 |
0.12 |
| Fever |
0 |
0.12 |
| Hospital |
0 |
0.12 |
| Pericarditis |
0 |
0.12 |
| Gout |
0 |
0.11 |
| Primary Immunodeficiency |
0 |
0.11 |
| Angina Pectoris |
0 |
0.1 |
| Tobacco Cessation |
0 |
0.1 |
| Reperfusion Injury |
0 |
0.09 |
| Artery |
0 |
0.06 |
| Aspirin |
0 |
0.06 |
| Beta-Adrenergic Agonist |
0 |
0.06 |
| Biomarker |
0 |
0.06 |
| C-Reactive Protein (CRP) |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Cyclosporine |
0 |
0.06 |
| Diet |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Exercise |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Injury |
0 |
0.06 |
| Inpatient Care |
0 |
0.06 |
| Interleukin |
0 |
0.06 |
| Meta-Analysis |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Neutrophils |
0 |
0.06 |
| Primary Care |
0 |
0.06 |
| Smoking |
0 |
0.06 |
| Stable Angina |
0 |
0.06 |
| Wound Management |
0 |
0.06 |